Current Report Filing (8-k)
May 06 2022 - 2:51PM
Edgar (US Regulatory)
0001728328
false
A1
0001728328
2022-05-05
2022-05-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 5, 2022
INMED
PHARMACEUTICALS INC.
(Exact
Name of Company as Specified in Charter)
British Columbia |
|
001-39685 |
|
98-1428279 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
InMed
Pharmaceuticals Inc.
Suite
310 - 815 W. Hastings Street,
Vancouver,
B.C.
Canada |
|
V6C
1B4 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Company’s
telephone number, including area code: (604) 669-7207
Not
applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common
Shares, no par value |
|
INM |
|
The
Nasdaq Stock Market LLC |
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01 Regulation FD Disclosure.
On
May 5, 2022, the Company announced that that its subsidiary, BayMedica, will be providing rare cannabinoids
for use in Radicle Science, Inc.’s Radicle Energy rare cannabinoid study to assess the effects of delta-9 (“d-9”) dominant
tetrahydrocannabivarin (“THCV”) on energy, focus/attention, appetite and weight/BMI.
The
information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by
reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following
exhibits shall be deemed to be furnished, and not filed:
Exhibit
No. |
|
Description |
99.1 |
|
News release, dated May 5, 2022 |
104 |
|
Cover Page Interactive Data File (embedded within the
Inline XBRL document and included as Exhibit 101) |
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
INMED PHARMACEUTICALS INC. |
|
|
|
Date: May 6, 2022 |
By: |
/s/ Brenda
Edwards |
|
|
Brenda Edwards
Interim,
Chief Financial Officer |
2
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024